Neuroblastoma and other adrenal tumors

The Surgery of Childhood Tumors

Volumn , Issue , 2008, Pages 201-225

  La Quaglia, Michael P ^a   Rutigliano, Daniel N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955682028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-540-29734-5_11     Document Type: Chapter

References (201)

1. Wright J (1910) Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med (12):556-561
2. Everson TC (1958) Spontaneous regression of cancer. Conn Med 22(9):637-643
3. Matthay KK, Villablanca JG, Seeger RC, et al. (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341(16):1165-1173
4. Moore K, Persaud T (1993) The developing human: Clinically oriented embryology, 5Thedn. W.B. Saunders, Philadelphia
5. Goodman M GJ, Smith M, Olshan A Symapathetic Nervous System Tumors (ICCC IV). National Cancer Insitute, SEER Program 1999
6. Nuchtern JG (2006) Perinatal neuroblastoma. Semin Pediatr Surg 15(1):10-16
7. Kramer S, Ward E, Meadows AT, et al. (1987) Medical and drug risk factors associated with neuroblastoma: A casecontrol study. J Natl Cancer Inst 78(5):797-804
8. Schwartzbaum JA (1992) Infl uence of the mother's prenatal drug consumption on risk of neuroblastoma in the child. Am J Epidemiol 135(12):1358-1367
9. Spitz MR, Johnson CC (1985) Neuroblastoma and paternal occupation. A case-control analysis. Am J Epidemiol 121(6):924-929
10. Wilkins JR, 3rd, Hundley VD (1990) Paternal occupational exposure to electromagnetic fields and neuroblastoma in off spring. Am J Epidemiol 131(6):995-1008
11. Bluhn EC, Daniels J, Pollock BH, Olshan AF (2006) Maternal use of recreational drugs and neuroblastoma in off spring: A report from the Children's Oncology Group (United States). Cancer Causes Control 17 663-669
12. Michalek AM, Buck GM, Nasca PC, et al. (1996) Gravid health status, medication use, and risk of neuroblastoma. Am J Epidemiol 143(10):996-1001
13. Daniels JL, Olshan AF, Pollock BH, et al. (2002) Breast-feeding and neuroblastoma, USA and Canada. Cancer Causes Control 13(5):401-405
14. French AE, Grant R, Weitzman S, et al. (2003) Folic acid food fortifi cation is associated with a decline in neuroblastoma. Clin Pharmacol Ther 74(3):288-294
15. Kushner BH, Gilbert F, Helson L (1986) Familial neuroblastoma. Case reports, literature review, and etiologic considerations. Cancer 57(9):1887-1893
16. Anderson J, Kempski H, Hill L, et al. (2001) Neuroblastoma in monozygotic twins-A case of probable twin-Totwin metastasis. Br J Cancer 85(4):493-496
17. Boyd TK, Schofield DE (1995) Monozygotic twins concordant for congenital neuroblastoma: Case report and review of the literature. Pediatr Pathol Lab Med 15(6):931-940
18. Bolande RP, Towler WF (1970) A possible relationship of neuroblastoma to Von Recklinghausen's disease. Cancer 26(1):162-175
19. Kushner BH, Hajdu SI, Helson L (1985) Synchronous neuroblastoma and von Recklinghausen's disease: A review of the literature. J Clin Oncol 3(1):117-120
20. Stovroff M, Dykes F, Teague WG (1995) The complete spectrum of neurocristopathy in an infant with congenital hypoventilation, Hirschsprung's disease, and neuroblastoma. J Pediatr Surg 30(8):1218-1221
21. Oguma E, Aihara T, Shimanuki Y, et al. (1996) Hypomelanosis of Ito associated with neuroblastoma. Pediatr Radiol 26(4):273-275
22. Shimada H, Ambros IM, Dehner LP, et al. (1999) The International Neuroblastoma Pathology Classifi cation (the Shimada system). Cancer 86(2):364-372
23. Lau L (2002) Neuroblastoma: A single institution's experience with 128 children and an evaluation of clinical and biological prognostic factors. Pediatr Hematol Oncol 19(2):79-89
24. Sano H, Bonadio J, Gerbing RB, et al. (2006) International neuroblastoma pathology classifi cation adds independent prognostic information beyond the prognostic contribution of age. Eur J Cancer 42(8):1113-1119
25. Goto S, Umehara S, Gerbing RB, et al. (2001) Histopathology (International Neuroblastoma Pathology Classifi cation) and MYCN status in patients with peripheral neuroblastic tumors: A report from the Children's Cancer Group. Cancer 92(10):2699-2708
26. Chatten J, Shimada H, Sather HN, et al. (1988) Prognostic value of histopathology in advanced neuroblastoma: A report from the Childrens Cancer Study Group. Hum Pathol 19(10):1187-1198
27. Tornoczky T, Kalman E, Kajtar PG, et al. (2004) Large cell neuroblastoma: A distinct phenotype of neuroblastoma with aggressive clinical behavior. Cancer 100(2):390-397
28. Kobayashi C, Monforte-Munoz HL, Gerbing RB, et al. (2005) Enlarged and prominent nucleoli may be indicative of MYCN amplifi cation: A study of neuroblastoma (Schwannian stroma-poor), undiff erentiated/poorly diff erentiated subtype with high mitosis-karyorrhexis index. Cancer 103(1):174-180
29. Look AT, Hayes FA, Nitschke R, et al. (1984) Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311(4):231-235
30. Taylor SR, Blatt J, Costantino JP, et al. (1988) Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer 62(4):749-754
31. Brodeur GM, Pritchard J, Berthold F, et al. (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466-1477
32. Brodeur GM, Seeger RC, Schwab M, et al. (1984) Amplifi cation of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121-1124
33. Benard J (1995) Genetic alterations associated with metastatic dissemination and chemoresistance in neuroblastoma. Eur J Cancer 31A(4):560-564
34. Weiss WA, Aldape K, Mohapatra G, et al. (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985-2995
35. Cohn SL, London WB, Huang D, et al. (2000) MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplifi ed MYCN. J Clin Oncol 18(21):3604-3613
36. Seeger RC, Brodeur GM, Sather H, et al. (1985) Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313(18):1111-1116
37. Seeger RC, Wada R, Brodeur GM, et al. (1988) Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene. Prog Clin Biol Res 271:41-49
38. Bagatell R, Rumcheva P, London WB, et al. (2005) Outcomes of children with intermediate-risk neuroblastoma aft er treatment stratifi ed by MYCN status and tumor cell ploidy. J Clin Oncol 23(34):8819-8827
39. George RE, London WB, Cohn SL, et al. (2005) Hyperdiploidy plus nonamplifi ed MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 23(27):6466-6473
40. Iehara T, Hosoi H, Akazawa K, Matsumoto Y et al. (2006) MYCN gene amplifi cation is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening. Br J Cancer 94 1510-1515
41. Azar CG, Scavarda NJ, Nakagawara A, et al. (1994) Expression and function of the nerve growth factor receptor (TRK-A) in human neuroblastoma cell lines. Prog Clin Biol Res 385:169-175
42. Brodeur GM, Nakagawara A, Yamashiro DJ, et al. (1997) Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 31(1-2):49-55
43. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. (1993) Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328(12):847-854
44. Schramm A, Schulte JH, Klein-Hitpass L, et al. (2005) Prediction of clinical outcome and biological characterization of neuroblastoma by expression profi ling. Oncogene 24(53):7902-7912
45. Suzuki T, Bogenmann E, Shimada H, et al. (1993) Lack of high-Affi nity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 85(5):377-384
46. Nakagawara A, Azar CG, Scavarda NJ, et al. (1994) Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14(1):759-767
47. Ho R, Eggert A, Hishiki T, et al. (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62(22):6462-6466
48. Jaboin J, Hong A, Kim CJ, et al. (2003) Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Lett 193(1):109-114
49. Yamashiro DJ, Liu XG, Lee CP, et al. (1997) Expression and function of Trk-C in favourable human neuroblastomas. Eur J Cancer 33(12):2054-2057
50. Lucarelli E, Kaplan D, Thiele CJ (1997) Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells. Eur J Cancer 33(12):2068-2070
51. Brodeur GM, Fong CT (1989) Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 41(2):153-174
52. Gilbert F, Balaban G, Moorhead P, et al. (1982) Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines. Cancer Genet Cytogenet 7(1):33-42
53. Fong CT, Dracopoli NC, White PS, et al. (1989) Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: Correlation with N-myc amplifi cation. Proc Natl Acad Sci 86(10):3753-3757
54. Caron H, van Sluis P, de Kraker J, et al. (1996) Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334(4):225-230
55. Caron H, van Sluis P, van Hoeve M, et al. (1993) Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplifi cation. Nat Genet 4(2):187-190
56. Maris JM, White PS, Beltinger CP, et al. (1995) Signifi cance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 55(20):4664-4669
57. Simon T, Spitz R, Faldum A, et al. (2004) New defi nition of low-risk neuroblastoma using stage, age, and 1p and MYCN status. J Pediatr Hematol Oncol 26(12):791-796
58. Oren M (1992) The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 11(2):141-148
59. Bown N, Cotterill S, Lastowska M, et al. (1999) Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340(25):1954-1961
60. Bown N, Lastowska M, Cotterill S, et al. (2001) 17q gain in neuroblastoma predicts adverse clinical outcome. U.K. Cancer Cytogenetics Group and the U.K. Children's Cancer Study Group. Med Pediatr Oncol 36(1):14-19
61. Lastowska M, Cotterill S, Pearson AD, et al. (1997) Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group. Eur J Cancer 33(10):1627-1633
62. Tajiri T, Tanaka S, Higashi M, et al. (2006) Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors. J Pediatr Surg 41(3):560-566
63. Lastowska M, Cullinane C, Variend S, et al. (2001) Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19(12):3080-3090
64. Maris JM, Matthay KK (1999) Molecular biology of neuroblastoma. J Clin Oncol 17(7):2264-2279
65. Goldsby RE, Matthay KK (2004) Neuroblastoma: Evolving therapies for a disease with many faces. Paediatr Drugs 6(2):107-122
66. Hiyama E, Yokoyama T, Hiyama K, et al. (2000) Multifocal neuroblastoma: Biologic behavior and surgical aspects. Cancer 88(8):1955-1963
67. Newton ER, Louis F, Dalton ME, et al. (1985) Fetal neuroblastoma and catecholamine-induced maternal hypertension. Obstet Gynecol 6(Suppl):49S-52S
68. Voute PA, Jr, Wadman SK, van Putten WJ. Congenital neuroblastoma (1970) Symptoms in the mother during pregnancy. Clin Pediatr 9(4):206-207
69. Jennings RW, LaQuaglia MP, Leong K, et al. (1993) Fetal neuroblastoma: Prenatal diagnosis and natural history. J Pediatr Surg 28(9):1168-1174
70. Antunes NL, Khakoo Y, Matthay KK, et al. (2000) Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol 22(4):315-320
71. Cooper R, Khakoo Y, Matthay KK, et al. (2001) Opsoclonus-myoclonus-Ataxia syndrome in neuroblastoma: Histopathologic features-A report from the Children's Cancer Group. Med Pediatr Oncol 36(6):623-629
72. Rudnick E, Khakoo Y, Antunes NL, et al. (2001) Opsoclonus-myoclonus- Ataxia syndrome in neuroblastoma: Clinical outcome and antineuronal antibodies-A report from the Children's Cancer Group Study. Med Pediatr Oncol 36(6):612-622
73. Boltshauser E, Deonna T, Hirt HR (1979) Myoclonic encephalopathy of infants or "dancing eyes syndrome". Report of 7 cases with long-Term follow-up and review of the literature (cases with and without neuroblastoma). Helv Paediatr Acta 34(2):119-133
74. Koh PS, Raffensperger JG, Berry S, et al. (1994) Long-Term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 125(5 Pt 1):712-716
75. Russo C, Cohn SL, Petruzzi MJ, et al. (1997) Long-Term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group. Med Pediatr Oncol 28(4):284-288
76. Numata K, Kusui H, Kawakatsu H, et al. (1997) Increased urinary HVA levels in neuroblastoma screens related to diet, not tumor. Pediatr Hematol Oncol 14(6):569-576
77. Asami T, Otabe N, Wakabayashi M, et al. (1995) Screening for neuroblastoma: A 9-year birth cohort-based study in Niigata, Japan. Acta Paediatr 84(10):1173-1176
78. Woods WG, Lemieux B, Leclerc JM, et al. (1994) Screening for neuroblastoma (NB) in North America: The Quebec Project. Prog Clin Biol Res 385:377-382
79. Woods WG, Tuchman M (1987) Neuroblastoma: The case for screening infants in North America. Pediatrics 79(6):869-873
80. Hanawa Y, Sawada T, Tsunoda A (1990) Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 18(6):472-475
81. Yamamoto K, Ohta S, Ito E, et al. (2002) Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: Cohort study in seven prefectures in Japan. J Clin Oncol 20(5):1209-1214
82. Woods WG, Tuchman M, Robison LL, et al. (1997) Screening for neuroblastoma is inEffective in reducing the incidence of unfavourable advanced stage disease in older children. Eur J Cancer 33(12):2106-2112
83. Kushner BH, Yeh SD, Kramer K, et al. (2003) Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 21(6):1082-1086
84. Kushner BH, Yeung HW, Larson SM, et al. (2001) Extending positron emission tomography scan utility to highrisk neuroblastoma: Fluorine-18 fl uorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 19(14):3397-3405
85. Kramer K, Kushner B, Heller G, et al. (2001) Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering Cancer Center Experience and A Literature Review. Cancer 91(8):1510-1519
86. Evans AE, D'Angio GJ, Randolph J (1971) A proposed staging for children with neuroblastoma. Children's cancer study group A. Cancer 27(2):374-378
87. Hayes FA, Green A, Hustu HO, et al. (1983) Surgicopathologic staging of neuroblastoma: Prognostic signifi cance of regional lymph node metastases. J Pediatr 102(1):59-62
88. D'Angio GJ, Evans AE, Koop CE (1971) Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1(7708):1046-1049
89. Evans AE, Chatten J, D'Angio GJ, et al. (1980) A review of 17 IV-S neuroblastoma patients at the Children's Hospital of Philadelphia. Cancer 45(5):833-839
90. Nickerson HJ, Nesbit ME, Grosfeld JL, et al. (1985) Comparison of stage IV and IV-S neuroblastoma in the first year of life. Med Pediatr Oncol 13(5):261-268
91. Cecchetto G, Mosseri V, De Bernardi B, et al. (2005) Surgical risk factors in primary surgery for localized neuroblastoma: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol 23(33):8483-8489
92. De Bernardi B, Pianca C, Pistamiglio P, et al. (2001) Neuroblastoma with symptomatic spinal cord compression at diagnosis: Treatment and results with 76 cases. J Clin Oncol 19(1):183-190
93. Katzenstein HM, Kent PM, London WB, et al. (2001) Treatment and outcome of 83 children with intaspinal neuroblastoma: The Pediatric Oncology Group experience. J Clin Oncol 19(4):1047-1055
94. Hayes FA, Thompson E, Hvizdala E (1984) Chemotherapy as an alternative to laminectomy and radiation in the management of epidural tumor. J Pediatr (104):221-224
95. Hayes FA, Green M, O'Connor DM (1989) Chemotherapeutic management of epidural neuroblastoma. Med Pediatr Oncol (17):6-8
96. Hoover ML, Crawford S, Cohn SL (1995) Long-Term outcome of patients with neuroblastoma and spinal compression. J Investig Med 43(Suppl 3):438A
97. Acharya S, Jayabose S, Kogan SJ, et al. (1997) Prenatally diagnosed neuroblastoma. Cancer 80:304-310
98. Sauvat F, Sarnacki S, Brisse H, et al. (2002) Outcome of suprarenal localized masses diagnosed during the perinatal period: A retrospective multi-center study. Cancer 94:2474-2480
99. Granata C, Fagnani AM, Gambini C, et al. (2000) Features and outcome of neuroblastoma detected before birth. J Pediatr Surg 35:88-91
100. Nishihira H, Toyoda Y, Tanaka Y, et al. (2000) Natural course of neuroblastoma detected by mass screening: 5-year prospective study at a single institution. J Clin Oncol 18(16):3012-3017
101. Holgersen LO, Subramanain S, Kripekar M, et al. (1996) Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 31(1):153-155
102. Kushner B, Cheung NK, La Quaglia MP, et al. (1996) International neuroblastoma staging system stage 1 neuroblastoma: A prospective study and literature review. J Clin Oncol 14:2174-2180
103. Nitschke R, SmiTheI, Shochat S, et al. (1988) Localized neuroblastoma treated by surgery: A Pediatric Oncology Group study. J Clin Oncol 6(8):1271-1279
104. Fritsch P, Kerbl R, Lackner H, et al. (2004) "Wait and see" strategy in localized neuroblastoma in infants: An option not only for cases detected by mass screening. Pediatr Blood Cancer 43(6):679-682
105. Perez CA, Matthay KK, Atkinson JB, et al. (2000) Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study. J Clin Oncol 18(1):18-26
106. Strother DR, Children's Oncology Group Phase III Study of Primary Surgical Therapy in Children With Low-Risk Neuroblastoma. COG-P9641
107. Strother DR, van Hoff J, Rao PV, et al. (1997) Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumor resection: Results from the Pediatric Oncology Group. Eur J Cancer 33(12):2121-2125
108. Nickerson HJ, Matthay KK, Seeger RC, et al. (2000) Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: A Children's Cancer Group study. J Clin Oncol 18(3):477-486
109. Guglielmi M, De Bernardi B, Rizzo A, et al. (1996) Resection of primary tumor at diagnosis in stage IV-S neuroblastoma: Does it affect the clinical course? J Clin Oncol 14(5):1537-1544
110. Kushner BH, Kramer K, Laquaglia MP, et al. (2006) Liver involvement in neuroblastoma: The memorial Sloan-Kettering experience supports treatment reduction in young patients. Pediatr Blood Cancer 46(3):278-284
111. Matthay KK, Perez C, Seeger RC, et al. (1998) Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study. J Clin Oncol 16(4):1256-1264
112. West DC, Shamberger RC, Macklis RM, et al. (1993) Stage III neuroblastoma over 1 year of age at diagnosis: Improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol 11(1):84-90
113. Look AT, Hayes FA, Shuster J, et al. (1991) Clinical relevance of tumor cell ploidy and N-myc gene amplifi cation in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9(4):581-591
114. Shamberger RC, SmiTheI, Joshi V, et al. (1998) The risk of nephrectomy during local control in abdominal neuroblastoma. J Pediatr Surg 33(2):161-164
115. Kushner B, La Quaglia MP, Bonilla MA, et al. (1994) Highly Effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12(12):2607-2613
116. Ladenstein R, Philip T, Lasset C, et al. (1998) Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol 16(3):953-965
117. Katzenstein HM, Cohn SL, Shore RM, et al. (2004) Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates wiThevent-free survival in high-risk neuroblastoma. J Clin Oncol 22(19):3909-3915
118. Matthay KK, Edeline V, Lumbroso J, et al. (2003) Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21(13):2486-491
119. Pinkerton CR (1991) ENSG 1-randomised study of highdose melphalan in neuroblastoma. Bone Marrow Transplant 7(Suppl 3):112-113
120. Matthay KK, O'Leary MC, Ramsay NK, et al. (1995) Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 31A(4):572-575
121. Matthay KK, Seeger RC, Reynolds CP, et al. (1994) Comparison of autologous and allogeneic bone marrow transplantation for neuroblastoma. Prog Clin Biol Res 385:301-307
122. Seeger RC, Reynolds CP, Gallego R, et al. (2000) Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children's Cancer Group Study. J Clin Oncol 18(24):4067-4076
123. Burchill SA, Lewis IJ, Abrams KR, et al. (2001) Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19(6):1795-1801
124. DuBois SG, Kalika Y, Lukens JN, et al. (1999) Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 21(3):181-189
125. Saarinen UM, Wikstrom S, Makipernaa A, et al. (1996) In vivo purging of bone marrow in children with poor-risk neuroblastoma for marrow collection and autologous bone marrow transplantation. J Clin Oncol 14(10):2791-2802
126. de Lagausie P, Berrebi D, Michon J, et al. (2003) Laparoscopic adrenal surgery for neuroblastomas in children. J Urol 170(3):932-935
127. La Quaglia MP, Kushner BH, Su W, et al. (2004) The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 39(3):412-417; discussion 412-417
128. Shorter NA, Davidoff AM, Evans AE, et al. (1995) The role of surgery in the management of stage IV neuroblastoma: A single institution study. Med Pediatr Oncol 24(5):287-291
129. Castel V, Tovar JA, Costa E, et al. (2002) The role of surgery in stage IV neuroblastoma. J Pediatr Surg 37(11):1574-1578
130. Koh CC, Sheu JC, Liang DC, et al. (2005) Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma. Pediatr Surg Int 21(2):69-72
131. Cheung NK, Kushner BH, LaQuaglia M, et al. (2001) N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 36(1):227-230
132. Kuroda T, Saeki M, Nakano M, et al. (2000) Surgical treatment of neuroblastoma with micrometastasis. J Pediatr Surg 35(11):1638-1642
133. Wolden SL, Gollamudi SV, Kushner BH, et al. (2000) Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 46(4):969-974
134. Haas-Kogan DA, Swift PS, Selch M, et al. (2003) Impact of radiotherapy for high-risk neuroblastoma: A Children's Cancer Group study. Int J Radiat Oncol Biol Phys 56(1):28-39
135. Haase GM, Meagher DP, Jr, McNeely LK, et al. (1994) Electron beam intraoperative radiation therapy for pediatric neoplasms. Cancer 74(2):740-747
136. Leavey PJ, Odom LF, Poole M, et al. (1997) Intra-operative radiation therapy in pediatric neuroblastoma. Med Pediatr Oncol 28(6):424-428
137. Abemayor E, Chang B, Sidell N (1990) Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett 55(1):1-5
138. Redfern CP, Lovat PE, Malcolm AJ, et al. (1995) Gene expression and neuroblastoma cell diff erentiation in response to retinoic acid: Diff erential Effects of 9-cis and all-Trans retinoic acid. Eur J Cancer 31A(4):486-494
139. Reynolds CP, Matthay KK, Villablanca JG, et al. (2003) Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197(1-2):185-192
140. Kohler JA, Imeson J, Ellershaw C, et al. (2000) A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma aft er high-dose therapy. Br J Cancer 83(9):1124-1127
141. George RE, Li S, Medeiros-Nancarrow C, Neuberg D et al. (2006) High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: Long-Term survival update. J Clin Oncol 24:2891-2896
142. Pole JG, Casper J, Elfenbein G, et al. (1991) High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 9(1):152-158
143. Castel V, Canete A, Melero C, et al. (2000) Results of the cooperative protocol (N-III-95) for metastatic relapses and refractory neuroblastoma. Med Pediatr Oncol 35(6):724-726
144. Blatt J, Fitz C, Mirro J, Jr (1997) Recognition of central nervous system metastases in children with metastatic primary extracranial neuroblastoma. Pediatr Hematol Oncol 14(3):233-241
145. Mastrangelo S, Tornesello A, Diociaiuti L, et al. (2001) Treatment of advanced neuroblastoma: Feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy. Br J Cancer 84(4):460-464
146. Troncone L, Rufini V, Luzi S, et al. (1995) The treatment of neuroblastoma with [131I]MIBG at diagnosis. Q J Nucl Med 39(Suppl 1):65-68
147. Garaventa A, Bellagamba O, Lo Piccolo MS, et al. (1999) 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients. Br J Cancer 81(8):1378-1384
148. Langler A, Christaras A, Abshagen K, et al. (2002) Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood-A phase-II-study. Klin Padiatr 214(4):153-156
149. Saylors RL, 3rd, Stine KC, Sullivan J, et al. (2001) Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 19(15):3463-3469
150. Vassal G, Doz F, Frappaz D, et al. (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21(20):3844-3852
151. Wagner LM, Crews KR, Iacono LC, et al. (2004) Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 10(3):840-848
152. Kushner BH, Kramer K, Cheung NK (1999) Oral etoposide for refractory and relapsed neuroblastoma. J Clin Oncol 17(10):3221-3225
153. Cheung NK, Kushner BH, Cheung IY, et al. (1998) Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 16(9):3053-3060
154. Kushner BH, Kramer K, Cheung NK (2001) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19(22):4189-4194
155. Revillon Y, Daher P, Jan D, et al. (1992) Pheochromocytoma in children: 15 cases. J Pediatr Surg 27(7):910-911
156. Bravo EL (1983) Pheochromocytoma. Current concepts in diagnosis, localization, and management. Prim Care 10(1):75-86
157. Fonkalsrud EW (1991) Pheochromocytoma in childhood. Prog Pediatr Surg 26:103-111
158. Goldfarb DA, Novick AC, Bravo EL, et al. (1989) Experience wiThextra-Adrenal pheochromocytoma. J Urol 142(4):931-936
159. Hodgkinson DJ, Telander RL, Sheps SG, et al. (1980) Extra-Adrenal intrathoracic functioning paraganglioma (pheochromocytoma) in childhood. Mayo Clin Proc 55(4):271-276
160. Rescorla FJ (2006) Malignant adrenal tumors. Semin Pediatr Surg 15(1):48
161. Pommier RF, Vetto JT, Billingsly K, et al. (1993) Comparison of adrenal and extraadrenal pheochromocytomas. Surgery 114(6):1160-1165; discussion 1165-1166
162. Sclafani LM, Woodruff JM, Brennan MF (1990) Extraadrenal retroperitoneal paragangliomas: Natural history and response to treatment. Surgery 108(6):1124-1129; discussion 1129-1130
163. Whalen RK, Althausen AF, Daniels GH (1992) Extra-Adrenal pheochromocytoma. J Urol 147(1):1-10
164. Sawin RS (1997) Functioning adrenal neoplasms. Semin Pediatr Surg 6(3):156-163
165. Neumann HP, Berger DP, Sigmund G, et al. (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329(21):1531-1538
166. Lairmore TC, Ball DW, Baylin SB, et al. (1993) Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 217(6):595-601; discussion 601-603
167. Neumann HP, Bausch B, McWhinney SR, et al. (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459-1466
168. Clements RH, Goldstein RE, Holcomb GW, 3rd (1999) Laparoscopic left adrenalectomy for pheochromocytoma in a child. J Pediatr Surg 34(9):1408-1409
169. Miller KA, Albanese C, Harrison M, et al. (2002) Experience with laparoscopic adrenalectomy in pediatric patients. J Pediatr Surg 37(7):979-982; discussion 979-982
170. Vargas HI, Kavoussi LR, Bartlett DL, et al. (1997) Laparoscopic adrenalectomy: A new standard of care. Urology 49(5):673-678
171. Bergada I, Venara M, Maglio S, et al. (1996) Functional adrenal cortical tumors in pediatric patients: A clinicopathologic and immunohistochemical study of a long term follow-up series. Cancer 77(4):771-777
172. Chudler RM, Kay R (1989) Adrenocortical carcinoma in children. Urol Clin North Am 16(3):469-479
173. Lack EE, Mulvihill JJ, Travis WD, et al. (1992) Adrenal cortical neoplasms in the pediatric and adolescent age group. Clinicopathologic study of 30 cases wiThemphasis on epidemiological and prognostic factors. Pathol Annu 27 Pt 1:1-53
174. Ribeiro RC, Michalkiewicz EL, Figueiredo BC, et al. (2000) Adrenocortical tumors in children. Braz J Med Biol Res 33(10):1225-1234
175. Lee PD, Winter RJ, Green OC (1985) Virilizing adrenocortical tumors in childhood: Eight cases and a review of the literature. Pediatrics 76(3):437-444
176. Decsi T, Soltesz G (1995) Aldosteronoma in children: A partial review of the literature. Eur J Pediatr 154(3):247
177. Etker S (1995) Aldosteronoma in childhood. J Pediatr Surg 30(7):1113
178. Cagle PT, Hough AJ, Pysher TJ, et al. (1986) Comparison of adrenal cortical tumors in children and adults. Cancer 57(11):2235-2237
179. Cift ci AO, Senocak ME, Tanyel FC, et al. (2001) Adrenocortical tumors in children. J Pediatr Surg 36(4):549-554
180. Sabbaga CC, Avilla SG, Schulz C, et al. (1993) Adrenocortical carcinoma in children: Clinical aspects and prognosis. J Pediatr Surg 28(6):841-843
181. Michalkiewicz E, Sandrini R, Figueiredo B, et al. (2004) Clinical and outcome characteristics of children with adrenocortical tumors: A report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol 22(5):838-845
182. Engstrom W, Lindham S, Schofield P (1988) Wiedemann-Beckwith syndrome. Eur J Pediatr 147(5):450-457
183. Sbragia-Neto L, Melo-Filho AA, Guerra-Junior G, et al. (2000) Beckwith-Wiedemann syndrome and virilizing cortical adrenal tumor in a child. J Pediatr Surg 35(8):1269-1271
184. Varley JM, Evans DG, Birch JM (1997) Li-Fraumeni syndrome-A molecular and clinical review. Br J Cancer 76(1):1-14
185. Ribeiro RC, Sandrini F, Figueiredo B, et al. (2001) An inherited p53 mutation that contributes in a tissue-specifi c manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci 98(16):9330-9335
186. Stewart JN, Flageole H, Kavan P (2004) A surgical approach to adrenocortical tumors in children: The mainstay of treatment. J Pediatr Surg 39(5):759-763
187. Meyer A, Niemann U, Behrend M (2004) Experience with the surgical treatment of adrenal cortical carcinoma. Eur J Surg Oncol 30(4):444-449
188. Ribeiro RC, Sandrini Neto RS, Schell MJ, et al. (1990) Adrenocortical carcinoma in children: A study of 40 cases. J Clin Oncol 8(1):67-74
189. Ribeiro RC, Sandrini R (1994) Adrenocortical carcinoma in children: Clinical aspects and prognosis. J Pediatr Surg 29(1):122
190. Taylor SR, Roederer M, Murphy RF (1987) Flow cytometric DNA analysis of adrenocortical tumors in children. Cancer 59(12):2059-2063
191. Venara M, Sanchez Marull R, Bergada I, et al. (1998) Functional adrenal cortical tumors in childhood: A study of ploidy, p53-protein and nucleolar
192. Pommier RF, Brennan MF (1992) An eleven-year experience with adrenocortical carcinoma. Surgery 112(6):963-970; discussion 970-971
193. Karakousis CP, Uribe J, Moore R (1981) Adrenal adenocarcinomas: Diagnosis and management. J Surg Oncol 16(4):385-389
194. Lubitz JA, Freeman L, Okun R (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223(10):1109-1112
195. Luton JP, Cerdas S, Billaud L, et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322(17):1195-1201
196. Chun HG, Yagoda A, Kemeny N, et al. (1983) Cisplatin for adrenal cortical carcinoma. Cancer Treat Rep 67(5):513-514
197. Hesketh PJ, McCaff rey RP, Finkel HE, et al. (1987) Cisplatin-based treatment of adrenocortical carcinoma. Cancer Treat Rep 71(2):222-224
198. Tattersall MH, Lander H, Bain B, et al. (1980) Cis-platinum treatment of metastatic adrenal carcinoma. Med J Aust 1(9):419-421
199. Ayass M, Gross S, Harper J (1991) High-dose carboplatinum and VP-16 in treatment of metastatic adrenal carcinoma. Am J Pediatr Hematol Oncol 13(4):470-472
200. Bukowski RM, Wolfe M, Levine HS, et al. (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: A Southwest Oncology Group study. J Clin Oncol 11(1):161-165
201. Percarpio B, Knowlton AH (1976) Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 15(4):288-292